NO982815L - Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet - Google Patents

Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet

Info

Publication number
NO982815L
NO982815L NO982815A NO982815A NO982815L NO 982815 L NO982815 L NO 982815L NO 982815 A NO982815 A NO 982815A NO 982815 A NO982815 A NO 982815A NO 982815 L NO982815 L NO 982815L
Authority
NO
Norway
Prior art keywords
ultra
menstrual bleeding
less
low dose
oral contraceptives
Prior art date
Application number
NO982815A
Other languages
English (en)
Norwegian (no)
Other versions
NO982815D0 (no
Inventor
Gary D Hodgen
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982815(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of NO982815D0 publication Critical patent/NO982815D0/no
Publication of NO982815L publication Critical patent/NO982815L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Confectionery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO982815A 1997-06-23 1998-06-18 Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet NO982815L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/880,419 US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
CA002256977A CA2256977C (fr) 1997-06-23 1998-12-23 Methodes de contraception orale comprenant une utilisation prolongee de l'agent contraceptif

Publications (2)

Publication Number Publication Date
NO982815D0 NO982815D0 (no) 1998-06-18
NO982815L true NO982815L (no) 1998-12-28

Family

ID=32043766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982815A NO982815L (no) 1997-06-23 1998-06-18 Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet

Country Status (10)

Country Link
US (2) US5898032A (fr)
EP (1) EP0911029B1 (fr)
JP (1) JPH1129481A (fr)
AT (1) ATE216241T1 (fr)
CA (1) CA2256977C (fr)
DE (1) DE69804918T2 (fr)
DK (1) DK0911029T3 (fr)
ES (1) ES2175650T3 (fr)
NO (1) NO982815L (fr)
PT (1) PT911029E (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP1148884A4 (fr) * 1998-11-12 2003-06-11 Warner Chilcott Lab Ireland Lt Contraceptif progestatif gradue
US6925809B2 (en) 1999-02-26 2005-08-09 R. Jan Mowill Gas turbine engine fuel/air premixers with variable geometry exit and method for controlling exit velocities
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
KR100988542B1 (ko) * 2001-06-18 2010-10-20 노벤 파머수티컬즈, 인코퍼레이티드 경피 시스템에서의 강화된 약물 전달
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
CN100581550C (zh) * 2001-12-05 2010-01-20 杜拉美德药物有限公司 预防怀孕和减少经期前症状的口服避孕药
EP1624848A4 (fr) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc Methodes de traitement hormonal faisant appel a des schemas contraceptifs a cycle prolonge
CN101001631B (zh) * 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
DE602004028256D1 (de) * 2003-09-04 2010-09-02 Pharmadesign Inc Behälter mit tablettenaufnahmehülsen zur lagerung und ausgabe von tabletten
WO2005032558A1 (fr) * 2003-10-01 2005-04-14 Janssen Pharmaceutica N.V. Regimes contraceptifs triphasiques etendus
EP1535618A1 (fr) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine
WO2005092441A2 (fr) * 2004-03-19 2005-10-06 Warner Chilcott Company, Inc. Procede de contraception orale multiphase a cycle prolonge
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea
JP2008515909A (ja) * 2004-10-07 2008-05-15 デュラメド ファーマシューティカルズ インコーポレーティッド 上昇用量延長サイクル療法を利用するホルモン処置の方法
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP1655031A1 (fr) 2004-10-08 2006-05-10 Schering AG Utilisation de dienogest pour contraceptives hormonelles avec cycle prolongué
US20060079491A1 (en) * 2004-10-08 2006-04-13 Andreas Sachse Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
CA2640432A1 (fr) * 2006-01-27 2007-08-09 Duramed Pharmaceuticals, Inc. Regimes pour traiter des conditions en rapport avec un manque d'oestrogene
EP1993531B1 (fr) * 2006-03-02 2015-10-14 Warner Chilcott Company, LLC Procédé de contraception orale multiphase à cycles prolongés
EP1930010A1 (fr) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Utilisation de valvérate d'estradiol ou de 17ß-estradiol combiné à du dienogest pour traiter par voie orale la récupération et/ou l'augmentation de la libido féminine
EP2055306A1 (fr) * 2007-11-05 2009-05-06 Bayer Schering Pharma AG Utilisation d'un gestagène associé à un ýstrogène et une ou plusieurs matières consommables secondaires/supports pharmaceutiquement acceptables pour la contraception orale sans lactose
JP2012502988A (ja) * 2008-09-16 2012-02-02 プレイテックス プロダクツ エルエルシー 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法
CA2740004A1 (fr) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Administration transdermique
US9198919B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
ES2734510T3 (es) 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
EP2410859A4 (fr) 2009-03-27 2013-03-13 Agile Therapeutics Inc Administration transdermique
HK1251938A1 (zh) * 2015-05-18 2019-05-03 敏捷治疗公司 避孕组合物及提高效能和调节副作用的方法
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen
WO2023037264A1 (fr) * 2021-09-07 2023-03-16 Millicent Pharma Limited Régime contraceptif comprenant un niveau réduit d'oestrogène

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
WO1998004246A2 (fr) 1996-07-26 1998-02-05 American Home Prod Contraceptif oral
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
CN100581550C (zh) 2001-12-05 2010-01-20 杜拉美德药物有限公司 预防怀孕和减少经期前症状的口服避孕药
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
EP1624848A4 (fr) 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc Methodes de traitement hormonal faisant appel a des schemas contraceptifs a cycle prolonge
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CN101001631B (zh) 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
DE602004028256D1 (de) 2003-09-04 2010-09-02 Pharmadesign Inc Behälter mit tablettenaufnahmehülsen zur lagerung und ausgabe von tabletten
WO2005032558A1 (fr) 2003-10-01 2005-04-14 Janssen Pharmaceutica N.V. Regimes contraceptifs triphasiques etendus

Also Published As

Publication number Publication date
PT911029E (pt) 2002-09-30
DE69804918T2 (de) 2002-11-07
EP0911029B1 (fr) 2002-04-17
DE69804918D1 (de) 2002-05-23
ATE216241T1 (de) 2002-05-15
CA2256977A1 (fr) 2000-06-23
US5898032A (en) 1999-04-27
DK0911029T3 (da) 2002-06-17
CA2256977C (fr) 2008-11-25
ES2175650T3 (es) 2002-11-16
USRE39861E1 (en) 2007-09-25
NO982815D0 (no) 1998-06-18
JPH1129481A (ja) 1999-02-02
EP0911029A2 (fr) 1999-04-28
EP0911029A3 (fr) 2000-03-29

Similar Documents

Publication Publication Date Title
NO982815D0 (no) Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkninsfullhet
ES2033850T3 (es) Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas.
LU91065I2 (fr) Drospirenone en combinaison avec oestradiol et leurs dérivés pharmaceutiquement acceptables (Allurene-Angeliq)
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
DE68928897D1 (de) Verfahren und system zur empfängnisverhütung
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
NZ591627A (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
HUP9900612A2 (hu) Új hormonális gyógyászati készítmények, valamint a készítmények alkalmazása ösztrogénpótlásra
DK0917466T3 (da) Oralt antikonceptionsmiddel
EP0803256A4 (fr) Medicaments destines a soulager les effets secondaires provoques par des immunodepresseurs
Olsson Vaginal rings for contraception: endocrine parameters
IT1243978B (it) Farmaco per uso umano, ad azione contraccettiva ed oncostatica preventiva, nei tumori del seno, dell'utero e nel melanoma.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application